AstraZeneca's blockbuster lung cancer drug boosts survival rates among patients, the pharma giant said yesterday.In a shot in the arm for the FTSE 100 group, a trial revealed that Imfinzi showed promise in treating highly aggressive small cell lung cancer. AstraZeneca said the trial demonstrated 'statistically significant and clinically meaningful improvement' in survival of patients.
Load More
Load More